Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.50 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31370072 | 0.94 | MDM4 (0.53) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL31370397 | 0.90 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL3724545 | 0.88 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL119590 | 0.88 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL16289406 | 0.88 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL3724266 | 0.88 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL119506 | 0.88 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL120599 | 0.88 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL19678478 | 0.88 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL119553 | 0.88 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349629-A1 | Angiotensin-1-Receptor Antagonists | FERRING B.V. (NL) | 2017-12-07 | — | — | US | disclosed |
| US-20170349629-A1 | Angiotensin-1-Receptor Antagonists | FERRING B.V. (NL) | 2017-12-07 | — | — | US | disclosed |
| WO-2017207760-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | FERRING B.V. (NL) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349629-A1 | Angiotensin-1-Receptor Antagonists | AGTR1, AGTR2, REN | MDM4 3483/4885TP53 4202/4885CASP3 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.